Alvarez & Marsal launched a life sciences business unit. Mark Freitas will lead the division and serve as managing director and life sciences practice leader. Freitas will be joined by Jim Cleffi, David Martin, Rich Rieger and Matt Sheldon as life sciences business unit managing directors and Daaron Dohler, Seth Rogers and Matt Staffier as senior directors.
Collectively, the new unit’s leadership team has combined experience across multiple disciplines and sectors, including pharmaceuticals, biotechnology, biopharmaceuticals, medical devices, medical technology, digital health and pharmaceutical services.
Leveraging Alvarez & Marsal’s operational heritage along with its corporate finance, strategic planning, board governance, mergers and acquisitions activity, risk management and compliance knowledge, the life sciences business unit will help clients navigate the life sciences industry landscape while capitalizing on opportunities.
“A&M’s life science business unit combines the firm’s legacy capabilities with its strong sector knowledge,” Tom Elsenbrook, managing director and leader of Alvarez & Marsal’s corporate performance improvement group, said. “Our results-driven mindset and customized solutions focus will help clients accelerate the development and commercialization of groundbreaking products.”
“The life sciences business unit is a natural evolution of our in-depth healthcare sector knowledge and our ability to drive changes that achieve clients’ goals and meet market demands,” Martin McGahan, a managing director and head of Alvarez & Marsal’s healthcare industry group, said. “The team’s combined expertise aligns with the firm’s operational orientation and augments our ability to develop sustainable solutions that promote growth.”
“A&M has developed an innovative approach to helping life sciences clients maximize value,” Freitas said. “An evolving industry landscape combined with a volatile economy requires an outcomes-driven approach that meets the urgency of clients’ current demands and anticipates those of tomorrow. The life sciences business unit launch marks a significant milestone for A&M, reinforcing the firm’s commitment to help clients bring purposeful innovations to market.”
